Rituximab: all 1,386 studies that test it
Page 9 of 14. Open to participants first (177), then studies with results posted, then the rest; newest registration first within each.
- A Study to Compare the Bioequivalence and Safety of JHL1101 and Rituximab in CD20 Positive B Cell Lymphoma PatientsTerminatedNCT03670888Phase 1
- Personalized Therapies in Inflammatory Complex DiseaseCompletedNCT03651518Phase 2
- Efficacy of First Line B-RI for Treatment Naive Waldenström's MacroglobulinemiaActive, not recruitingNCT03620903Phase 2
- Low-dose ITI Strategy for Children in Hemophilia A With High-titer Inhibitor and Poor ITI Risk in ChinaStatus unknownNCT03598725Phase 4
- Rituximab Plus MG4101 Indolent CD20-positive Non-Hodgkin Lymphoma (NHL)TerminatedNCT03578198Phase 2
- Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System LymphomaTerminatedNCT03558750Phase 1
- T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic AnemiaActive, not recruitingNCT03531736Phase 1
- Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)CompletedNCT03527147Phase 1
- Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLLCompletedNCT03524235Phase 1
- Copanlisib and Rituximab in Marginal Zone Lymphoma PatientsActive, not recruitingNCT03474744Phase 2
- A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLLActive, not recruitingNCT03467867Phase 2
- Study of TQB2303 in Patients With Aggressive CD20 Positive Non-Hodgkin's LymphomaStatus unknownNCT03456466Phase 1/2
- Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic LeukemiaCompletedNCT03455517Phase 2
- INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)CompletedNCT03424122Phase 1
- Trial of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With RituximabCompletedNCT03384277Phase 4
- Phase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell LymphomaCompletedNCT03372837Phase 3
- Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and AdolescentsWithdrawnNCT03349346Phase 1
- Safety of HMA-CD20 in Patients With HFrEFStatus unknownNCT03332888Phase 2
- Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell LymphomaActive, not recruitingNCT03321643Phase 1
- Comparison of Clinical Effects of Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis PatientsCompletedNCT03315923Phase 2/3
- Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic SyndromeStatus unknownNCT03298698Phase 3
- Randomized Clinical Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane PemphigoidActive, not recruitingNCT03295383Phase 3
- Immunoadsorption Therapy in Managing NMDAR Antibodies EncephalitisCompletedNCT03274375Phase 2
- The Study of Different Dose Rituximab in the Treatment of ITPCompletedNCT03258866Phase 4
- A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6CompletedNCT03255096Phase 1
- Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell LymphomaWithdrawnNCT03232307Phase 2
- Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by ChemiotherapyTerminatedNCT03225924Phase 1/2
- IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2Active, not recruitingNCT03194815Phase 2
- Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell LymphomaTerminatedNCT03189836Phase 1
- Risk Adapted Therapy in Diffuse Large B Cell LymphomaStatus unknownNCT03188198Phase 2
- Effect of Rituximab in Treatment of Membranoproliferative GlomerulonephritisStatus unknownNCT03180723Phase 3
- QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHLWithdrawnNCT03169790Phase 1/2
- Maintenance of Remission With Rituximab Versus Azathioprine for Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis.CompletedNCT03164473Phase 3
- A Study of JHL1101 Versus MabThera® in Subjects With Severe Rheumatoid ArthritisTerminatedNCT03161457Phase 1
- Metronomic Chemotherapy in Elderly Non-fit Patients With Aggressive B-Cell LymphomasCompletedNCT03161054Phase 2
- Efficacy and Safety Assessment of a Treatment Combining Rituximab and Belimumab in Adults With Persistent Immune ThrombocytopeniaCompletedNCT03154385Not applicable
- Rituximab in Patients With Acute ST-elevation Myocardial Infarction StudyCompletedNCT03072199Phase 1/2
- Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab TherapyCompletedNCT03069703Phase 2
- Treatment of Follicular Lymphoma With High Dose Therapy and Stem Cell Support Followed by Rituximab and Alpha InterferonCompletedNCT03069248Phase 2
- Rituximab Objective Outcome Measures Trial in SLEStatus unknownNCT03054259Phase 2
- Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous NephropathyStatus unknownNCT03018535Phase 3
- The PROLONG Trial - Rituximab Maintenance Therapy in ITPCompletedNCT03010202Phase 3
- A Study Comparing GB241 And Rituximab in Patients With B-cell Non-Hodgkin's LymphomaCompletedNCT03003039Phase 1
- Evaluation of Efficacy and Safety of Rituximab With Mycophenolate Mofetil in Patients With Interstitial Lung DiseasesCompletedNCT02990286Phase 3
- Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisPTerminatedNCT02983097Phase 1/2
- PCD Versus RCD for the Treatment of Patients With Waldenstrom's MacroglobulinemiaStatus unknownNCT02971982Phase 1/2
- Rituximab Combined With MSCs in the Treatment of PNS (3-4 Stage of CKD)Status unknownNCT02966717Phase 2
- Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT02960646Phase 1
- A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)TerminatedNCT02957019Phase 1/2
- Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 MutationCompletedNCT02950051Phase 3
- A Study to Assess the Pharmacokinetics and Safety of Recombinant Human Murine Chimeric Anti CD20 Monoclonal Antibody Injection (IBI301) Compared to Rituximab Injection in CD20 Positive B Cell Lymphoma PatientsCompletedNCT02945215Phase 1
- A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's LymphomaTerminatedNCT02914938Phase 1
- Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified TreatmentCompletedNCT02881086Phase 3
- Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell LymphomaStatus unknownNCT02871869Phase 2/3
- A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma PatientsCompletedNCT02867566Phase 3
- Multiple Fields Radiotherapy Versus Intravenous Rituximab in the Treatment of Indolent Cutaneous Lymphomas B-cell With Multiple or Recurrent LesionsStatus unknownNCT02867553Phase 3
- EDOCH Alternating With DHAP for New Diagnosed Younger MCLCompletedNCT02858804Phase 4
- The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström MacroglobulinemiaCompletedNCT02844322Phase 4
- Rituximab, Eltrombopag and Dexamethasone as Frontline Treatment for Immune ThrombocytopeniaStatus unknownNCT02834286Phase 2
- Rituximab in Eosinophilic Granulomatosis With PolyangiitisCompletedNCT02807103Phase 3
- Phase II Prospective Trial of Addition of Rituximab to Reduced Dose CHOP Chemotherapy in DLBC L Patients Aged 65 Years and OverStatus unknownNCT02792491Phase 2
- Treatment of Granulomatous and Lymphocytic Interstitial Lung Disease in Patients With Common Variable ImmunodeficiencyWithdrawnNCT02789397Phase 2
- Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic LeukemiaCompletedNCT02779283Phase 1
- Study of ACTR087 in Subjects With Relapsed or Refractory B-cell LymphomaCompletedNCT02776813Phase 1
- CyBeR Association in Relapsed/Refractory DLBCLStatus unknownNCT02758925Phase 2
- Treatment of ITP With Rituximab and / or AccutaneStatus unknownNCT02757196Phase 2
- Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell LymphomaStatus unknownNCT02753062Phase 2
- Reduced Chemotherapy in Low Risk DLBCLStatus unknownNCT02752815Phase 4
- An Evaluation AZD2014 Alone and in Combination With Rituximab in Relapsed/Refractory Diffuse Large B Cell LymphomaCompletedNCT02752204Phase 2
- RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis.CompletedNCT02746744Phase 3
- Clinical Trial to Evaluate Efficacy and Safety of Acellbia® (JSC "BIOCAD") With Methotrexate in First Line Biological Therapy of Patients With Active Rheumatoid ArthritisCompletedNCT02744196Phase 3
- A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell LymphomaWithdrawnNCT02735876Phase 3
- A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)Active, not recruitingNCT02734771Phase 2
- Rituximab (RTX) for Disease Modifying Anti Rheumatic Drug (DMARD) Non-responders in Pakistan: The Pakistan Rituximab Study (PARIS)CompletedNCT02731560Phase 4
- Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell LymphomaCompletedNCT02728531Phase 1
- Treatment of IgG4-Related Disease With Revlimid and RituximabCompletedNCT02705638Phase 1
- A Study to Evaluate the Efficacy and Safety of Mabthera Alone and in Combination With Either Cyclophosphamide or Methotrexate in Patients With Rheumatoid ArthritisCompletedNCT02693210Phase 2
- Bendamustine and Rituximab Combination Therapy for Cold Agglutinin DiseaseCompletedNCT02689986Phase 2
- Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCLActive, not recruitingNCT02682641Phase 2
- Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell LymphomaCompletedNCT02670616Phase 2
- Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in RemissionActive, not recruitingNCT02632396Phase 1/2
- Rituximab for the Otolaryngologic Manifestations of Granulomatosis With PolyangiitisTerminatedNCT02626845Phase 4
- Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomaWithdrawnNCT02623920Phase 2
- Rituximab in Recurrent IgA NephropathyStatus unknownNCT02571842Phase 4
- Rituximab Plus Corticosteroids in Non-infectious Active Mixed Cryoglobulinemia VasculitisTerminatedNCT02556866Phase 2
- Intrathecal Rituximab in Progressive Multiple SclerosisCompletedNCT02545959Phase 2
- Immune Modulation Therapy for Pompe DiseaseStatus unknownNCT02525172Phase 4
- Rapid Infusion Rituximab, Hematologic, Oncologic, and Rheumatologic DisordersCompletedNCT02484053Early Phase 1
- MabionCD20® Compared to MabThera® in Patients With Rheumatoid ArthritisCompletedNCT02468791Phase 3
- A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell LymphomaCompletedNCT02460276Phase 2
- A Study of Escalating Doses of DCDS0780A in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's LymphomaCompletedNCT02453087Phase 1
- Efficacy and Safety of Rituximab to That of Calcineurin Inhibitors in Children With Steroid Dependent Nephrotic SyndromeCompletedNCT02438982Phase 3
- Comparison Between a Long Term and a Conventional Maintenance Treatment With RituximabCompletedNCT02433522Phase 3
- Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell LymphomaActive, not recruitingNCT02427620Phase 2
- Bendamustine in Combination With Rituximab as a First-line Therapy Followed by Maintenance Therapy With Rituximab in Patients With Follicular LymphomaStatus unknownNCT02423837Phase 3
- Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) PatientsWithdrawnNCT02420938Phase 2
- Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)WithdrawnNCT02408042Phase 1/2
- BNHL-2015 for Children or Adolescents in ChinaActive, not recruitingNCT02405676Phase 2/3
- Brentuximab for Newly Diagnosed Hodgkin DiseaseCompletedNCT02398240Phase 2
- Efficacy and Safety of Rituximab to That of Calcineurin Inhibitors in Children With Steroid Resistant Nephrotic SyndromeStatus unknownNCT02382575Phase 4